KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Treasury Shares (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Treasury Shares for 14 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 30.76% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 30.76% increase, with the full-year FY2025 number at $1.0 billion, up 30.76% from a year prior.
  • Treasury Shares was $3.3 million for Q4 2025 at Bio-Rad Laboratories, roughly flat from $3.3 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $3.3 million in Q3 2025 to a low of $279544.0 in Q4 2021.
  • A 5-year average of $1.5 million and a median of $1.1 million in 2023 define the central range for Treasury Shares.
  • Biggest YoY gain for Treasury Shares was 147.99% in 2022; the steepest drop was 29.1% in 2022.
  • Bio-Rad Laboratories' Treasury Shares stood at $106.3 million in 2021, then skyrocketed by 147.99% to $263.6 million in 2022, then soared by 139.96% to $632.5 million in 2023, then rose by 22.07% to $772.1 million in 2024, then skyrocketed by 30.76% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Treasury Shares are $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025).